Copyright
©The Author(s) 2015.
World J Hepatol. Mar 27, 2015; 7(3): 521-531
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.521
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.521
Characteristics | Cohort 1(n =139) | Cohort 2(n = 82) | Cohort 3(n = 100) |
Age, median, yr (95%CI) | 67 (65-68) | 63 (60-69) | 68.5 (66-71) |
Sex, M/F | 84/16 | 90/10 | 88/12 |
Cirrhosis or advanced fibrosis (F3) | 100 | 100 | 94 |
Aetiology: Virus/alcohol/virus + alcohol/ NASH | 47/35/6/10 | 49/29/9/7 | 27/46/6/8 |
Child-Pugh score: A/B | 69/31 | 75/25 | 95/5 |
BCLC A/B/C | 47/34/19 | 34/46/20 | 10/81/9 |
Infiltrative tumours | 17 | 22 | 2 |
Segmental portal vein thrombosis | 15 | 19.5 | 9 |
AFP < 200 ng/mL | 78 | 60 | 77 |
AFP ≥ 200 ng/mL | 22 | 40 | 23 |
Diagnosis based on: Imaging/ biopsy | 85/15 | 77/23 | 80/20 |
Incidental/screening/symptoms | 17/70/13 | 31/53/16 | 19/66/15 |
Previous treatments (surgery, RFA) | 15 | 15 | 18 |
- Citation: Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? World J Hepatol 2015; 7(3): 521-531
- URL: https://www.wjgnet.com/1948-5182/full/v7/i3/521.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i3.521